Kura Oncology Inc. has highlighted key developments in its latest corporate presentation. The company announced the approval of KOMZIFTI (ziftomenib) for the treatment of adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). Kura retains leadership and key strategic rights to ziftomenib in the U.S., while engaging in a 50/50 co-development and co-promotion partnership, with Kura booking all U.S. sales and leading global development. The company is pursuing a comprehensive clinical development strategy for ziftomenib, including combination therapies and studies targeting up to 50% of AML patients. Additional pipeline advancements include the development of KO-7246, a next-generation menin inhibitor for diabetes and cardiometabolic diseases, and ongoing research into darlifarnib combination regimens in solid tumors such as RCC and KRASG12C-mutant cancers. Kura also plans to expand its pipeline with assets targeting solid tumors, including ER+ driven tumors. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.
Comments